Potential role of ustekinumab in the treatment of chronic plaque psoriasis

Biologics: Targets and Therapy

Volumn 4, Issue , 2010, Pages 119-129

  Mercuri, Santo Raffaele ^a   Naldi, Luigi ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Chronic plaque psoriasis; Ustekinumab

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; HYDROXYUREA; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; METHOTREXATE; PLACEBO; PSORALEN; RETINOID; USTEKINUMAB;

ARTHRALGIA; BACKACHE; COMORBIDITY; COUGHING; CYTOKINE RELEASE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; IC50; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; KERATINOCYTE; MALIGNANT NEOPLASM; NONHUMAN; PHARMACODYNAMICS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SALMONELLOSIS; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VOLUME OF DISTRIBUTION;

EID: 79953879634     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol. 2006;126:1438-1440.
2. Nijsten T, Wakkee M. Complexities of the association between psoriasis and comorbidities. J Invest Dermatol. 2009;129:1601-1163.
3. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005;64 Suppl 2:ii3-ii8.
4. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-128.
5. Naldi L, Minelli C. Dermatology. In: Machin D, Day S, Green S, editors. Textbook of Clinical Trials. Chichester, UK: John Wiley & Sons, Ltd; 2006. p. 263-285.
6. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol. 2007;25:547-554.
7. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194-199.
8. EMEA Committee for Proprietary Medical Products. Note for guidance on clinical investtigation of medical products indicated for the treatment of psoriasis. CPMP/EWP 2454/02.
9. Silman AJ, Hochberg MC. Psoriatic arthropathy. In: Epidemiology of the rheumatic diseases. New York: Oxford University Press; 1993:86-104.
10. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61-67.
11. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007;167:1670-1675.
12. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses’ Health Study II. Am J Med. 2007;120:953-959.
13. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-1499.
14. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383-392.
15. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78:827-851.
16. Nair R, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kB pathways. Nat Genet. 2009;41:199-204.
17. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128:1653-1661.
18. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008;128:1064-1067.
19. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Vatan L, Szeliga W, et al. Induction of memory IL-17??T cell trafficking and expansion by IFN-gamma: Mechanism and pathological relevance. J Immunol. 2008;181:4733-4741.
20. Nestle FO, Kaplan DH, Barker JN. Psoriasis. N Engl J Med. 2009;361:496-509.
21. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339-1350.
22. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725.
23. Pirhonen J, Matikainen S, Julkunen I. Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol. 2002;169:5673-5678.
24. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699-5708.
25. Lee J, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. Exp Med. 2004;199:125-130.
26. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11:16-23.
27. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006; 203:2673-2682.
28. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, et al. A critical function for transforming growth factor-beta, interleukin-23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9:650-657.
29. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis. 2004;190:624-631.
30. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2557-2587.
31. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207-1211.
32. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36:1309-1323.
33. Naldi L, Rzany B. Chronic plaque psoriasis. Clin Evid. 2009;pii:1706.
34. Katz KA. “Biologics”: a clinically meaningless term. Br J Dermatol. 2006;154:809-812.
35. Van de Kerkhof PCM, De Hoop D, De Korte J, Cobelens SA, Kuipers MV. Patient Compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200:292-298.
36. Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, et al. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2009 Oct 21. [Epub ahead of print].
37. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010 Feb 9. [Epub ahead of print].
38. Kamili QA, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol. 2010;9:57-60.
39. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses of a large US observational study. Arthritis Rheum. 2007;56:2886-2895.
40. Kwon HJ, Coté TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807-811.
41. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-2869.
42. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716-720.
43. Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn’s disease. Inflamm Bowel Dis. 2006;12:558-565.
44. Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, et al. A phase I, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23:1081-1092.
45. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modelling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate-to-severe plaque psoriasis. J Clin Pharmacol. 2009;49:162-175.
46. Zhou H, Davis H M. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today. 2009;14:891-898.
47. Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, Davis HM. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010;50:257-267.
48. Leonard JP, Waldburger KE, Schaub RG, Smith T, Hewson AK, Cuzner ML, et al. Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Crit Rev Immunol. 1997;17:545-553.
49. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281-1290.
50. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cellmediated pathology in a mouse model of psoriasislike skin inflammation. J Clin Invest. 2008;118:597-607.
51. Kauffman CL, Aria N, Toichi E, McCormick TE, Cooper KD, Gottlieb AB, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123:1037-1044.
52. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006;177:4917-4926.
53. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. CNTO 1275 Psoriasis Study Group, A human interleukin-12/23 monoclonal antibody for the treatment of plaque psoriasis. N Eng J Med. 2007;356:580-592.
54. Leonardi CL CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX1). Lancet. 2008;371:1665-1674.
55. Papp AK, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX2). Lancet. 2008;371:1675-1684.
56. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-128.
57. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo controlled, crossover trial. Lancet. 2009;373:605-606.
58. Elliott M, Benson J, Blank M, et al. Ustekinumab: lessons learned from targeting Interlukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci. 2009;1182:97-110.
59. Meeran SM, Mantena SK, Meleth S, Elmets CA, Katiyar SK. Interleukin-12-deficient mice are at greater risk of UV radiationinduced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther. 2006;5:825-832.
60. Langowski JL, Zhang X, Wu L, Basham B, McClanahan T, Kastelein RA, Oft M. IL-23 promotes tumor incidence and growth. Nature. 2006;442:461-465.
61. Holscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, Alber G, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol. 2001;167:6957-6966.
62. Wang Y, Chaudhri G, Jackson RJ, Karupiah G. IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol. 2009;183:3324-3331.
63. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998;280:1432-1435.
64. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280:1435-1438.
65. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-Guidelines on the systemic treatment ofpsoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:5-70.
66. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019.